Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 20;5(5):320-7.
doi: 10.7150/jca.8748. eCollection 2014.

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study

Teresa Gamucci  1 , Andrea Michelotti  2 , Laura Pizzuti  3 , Lucia Mentuccia  1 , Elisabetta Landucci  2 , Isabella Sperduti  4 , Luigi Di Lauro  3 , Alessandra Fabi  5 , Giuseppe Tonini  6 , Valentina Sini  7 , Nello Salesi  8 , Ilaria Ferrarini  2 , Angela Vaccaro  1 , Ida Pavese  9 , Enzo Veltri  8 , Luca Moscetti  10 , Paolo Marchetti  7 , Patrizia Vici  3
Affiliations

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study

Teresa Gamucci et al. J Cancer. .

Abstract

Background: Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes and after two or more chemotherapy lines for advanced disease.

Objectives: This multicenter observational retrospective study was performed in order to evaluate activity and tolerability of eribulin in real-world patient population.

Methods: 133 advanced breast cancer patients pretreated with ≥ 2 chemotherapy lines for metastatic disease were retrospectively enrolled in the observational trial in 11 italian cancer centres.

Results: A median of 5 cycles of eribulin (range, 1-15) were administered. Twenty-eight partial responses were observed, for an overall response rate of 21.1% (95%CI,14.1-28.0). A stable disease was recorded in 57 patients (42.8%), and a clinical benefit (response or stable disease lasting ≥ six months) was observed in 51 patients (38.3%, 95%CI, 30.1-46.6). The subgroup analysis showed that a significant improvement in term of partial response and clinical benefit was achieved when eribulin was administered in HER-2 negative tumors (p=0.01 and p=0.004, respectively) and when it is given as third-line (p=0.09 and p=0.02, respectively). Toxicity was manageable; fatigue is the most common side effect observed, usually of low-grade, and clearly cumulative-dose related.

Conclusions: In this retrospective, observational analysis eribulin confirmed its efficacy and manageable tolerability even in real-world population and in heavily pretreated patients.

Keywords: advanced breast cancer; chemotherapy.; eribulin mesylate; heavily pretreated patients; real-world population.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Progression free survival (a) and overall survival (b).
Figure 1
Figure 1
Progression free survival (a) and overall survival (b).
See this image and copyright information in PMC

References

    1. El Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol. 2011;80:433–49. - PubMed
    1. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc. 2009;84:533–45. - PMC - PubMed
    1. Jordan MA, Kamath K, Manna T. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086–95. - PubMed
    1. Smith JA, Wilson L, Azarenko O. et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49:1331–7. - PMC - PubMed
    1. Towle MJ, Salvato KA, Wels BF. et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011;71:496–505. - PubMed